Tempus AI (TEM) Unveils Cancer Test Kit, Soars 13.9% [Yahoo! Finance]
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Yahoo! Finance
Tempus AI extended its winning streak to a 3rd straight session on Wednesday, surging 13.89 percent to close at $56.41 apiece, as investors took heart from the official launch of a new test kit capable of detecting cancer from a blood sample alone. In an updated report, Tempus AI Inc. (NASDAQ:TEM) said that it partnered with Predicta Biosciences—a precision oncology company—for the launch of the GenoPredicta test kit, which can extract deep insights from a blood sample or bone marrow with as few as 50 cancer cells. Photo from Tempus AI website Tempus AI Inc. (NASDAQ:TEM) said that the test kit is so sensitive that it can track cancer even in individuals who previously did not have enough detectable cancer cells for analysis. The test kit would support medical practitioners and researchers in the accurate diagnosis of cancer, in figuring out how severe the disease is, identifying if drugs or therapies work, and tracking for cancer cells left after treatment. "GenoPredicta of
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD MonitoringBusiness Wire
- Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026Business Wire
- Tempus AI (TEM) was upgraded by TD Cowen from "hold" to "buy". They now have a $65.00 price target on the stock.MarketBeat
- Tempus AI (TEM) is now covered by Jefferies Financial Group Inc.. They set an "underperform" rating and a $35.00 price target on the stock.MarketBeat
- Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant CareBusiness Wire
TEM
Earnings
- 2/24/26 - Beat
TEM
Sec Filings
- 4/15/26 - Form 144
- 4/7/26 - Form ARS
- 4/7/26 - Form DEFA14A
- TEM's page on the SEC website